- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – February 2013
The Hallmarks of Cancer – 12 years on
What does it take to write a paper that will be cited more than 12,000 times? In the case of Douglas Hanahan and Robert Weinberg, it was a day spent discussing the features common to all cancer cells. While the field of cancer cell biology was becoming dauntingly complex, they came up with a straightforward framework for understanding the cancer cell: it had, they said, six underlying essential features. The paper that brought these ideas together, The Hallmarks of Cancer, went on to become a publishing sensation.
More than 10 years on, they updated the paper and introduced another two potential hallmarks, but their basic idea has stood the test of time. Doug Hanahan (Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland) gave the keynote lecture at ESMO 2012; Helen Saul caught up with him there.